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Background: Mugwort pollen allergens represent the main cause of pollinosis in late summer. The major allergen, Art v
1, contains only one single immunodominant, solely HLA-DR-restricted T cell epitope (Art v 125-36). The frequency of HLA-
DRB1*01 is highly increased in mugwort-allergic individuals and HLA-DR1 serves as restriction element for Art v 125-36.
However, Art v 125-36 also binds to HLA-DR4 with high affinity and DR1-restricted Art v 125-36 -specific T cell receptors can
be activated by HLA-DR4 molecules. To understand the predominance of HLA-DR1 in mugwort allergy in spite of the
degeneracy in HLA/peptide-binding and TCR-recognition, we investigated the molecular background of Art v 125-36
/MHC/TCR interactions in the context of HLA-DR1 compared to -DR4.
Results: The majority of Art v 125-36 -specific T cell lines and clones from HLA-DR1 carrying, mugwort pollen-allergic
donors reacted to synthetic and naturally processed Art v 1–peptides when presented by HLA-DR1 or HLA-DR4
expressing antigen presenting cells. However, at limiting peptide concentrations DR1 was more effective in T cell
stimulation. In addition, the minimal epitope for 50% of Art v 125-36 -specific T cells was shorter for DR1 than for DR4. In
vitro binding assays of Art v 125-36 mutant peptides to isolated DR1- and DR4-molecules indicated similar binding
capacities and use of the same register. In silico simulation of Art v 125-36 binding to HLA-DR1 and -DR4 suggested similar
binding of the central part of the peptide to either molecule, but a higher flexibility of the N- and C-terminal amino acids
and detachment at the C-terminus in HLA-DR1.
Conclusions: The predominance of HLA-DR1 in the response to Art v 125-36 may be explained by subtle conformation
changes of the peptide bound to DR1 compared to DR4. Computer simulation supported our experimental data by
demonstrating differences in peptide mobility within the HLA-DR complex that may influence TCR-binding. We suggest
that the minor differences observed in vitro may be more relevant in the microenvironment in vivo, so that only
presentation by HLA-DR1, but not -DR4 permits successful T cell activation.
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CD4+ T helper (Th) cells play a major role in the induc-
tion and maintenance of IgE-mediated allergy [1], which
is characterized by an excessive Th2 response. The Th2-
cytokines, interleukin-4 and interleukin-13, lead to the
production of allergen-specific IgE antibodies which
bind to high affinity receptors on effector cells. Upon
renewed allergen contact, cross-linking of these IgE anti-
bodies leads to the release of inflammatory mediators,
which cause allergic symptoms. Allergen-specific CD4+
Th cells recognize their cognate peptide via their T cell
receptor (TCR) in the context of self major histocom-
patibility complex (MHC) class II molecules on the sur-
face of antigen presenting cells (APC). Binding of the
processed peptides to the human leukocyte antigen
(HLA) class II molecules HLA-DR, -DP or –DQ occurs
in endosomal compartments and is facilitated by
accessory molecules. These HLA class II molecules are
highly polymorphic within the population and for many
immunogenic peptides degenerate binding to different
MHC-class II molecules has been described. This feature
is of interest for instance in vaccine development as it
would allow presentation of such T cell epitopes on APC
within a wide population range [2,3]. Besides, also for
TCR a plasticity in ligand recognition, i.e. degeneracy in
peptide reactivity as well as cross-recognition in the con-
text of distinct MHC-molecules has been found [4,5].
In Europe and parts of Asia, mugwort (Artemisia vul-
garis) pollen causes the most prevalent pollen allergy in
late summer and autumn. Mugwort pollen contains only
one major allergen, Art v 1, recognized by IgE in 95% of
mugwort pollen-allergic individuals [6]. In contrast to
other relevant major allergens, Art v 1 contains only one
single immunodominant T cell epitope, Art v 125-36
(KCIEWEKAQHGA) which is recognized by more than
80% of Art v 1-reactive mugwort pollen-allergic patients
[7]. The presentation of Art v 125–36 is exclusively HLA-
DR-restricted and is highly associated with the HLA-
DR1 phenotype [8]. Other associations between HLA
class II phenotypes and allergic responses to major aller-
gens are by far less strong [9].
Although the T cell response to Art v 125-36 is clearly
associated with HLA-DR1, we previously found Art v
125-36–specific T cells restricted by HLA-DR3, -DR16 or
-DR15 in the minor fraction of DR1-negative patients
[10]. Accordingly, the peptide showed degenerate high
affinity binding to several HLA-DR alleles [10]. We also
observed that specific T cell activation was inducible by
APC expressing DR4 or other non-DR1-HLA alleles
suggesting TCR cross-recognition. Although DR4
seemed to be able to present the immunodominant Art
v 1 epitope, the frequency of DR4 in our Art v 1-reactive
patient group (10,7%; n = 75) is not increased compared
to the normal population (16%; n = 100). Notably, wehave also not been able to isolate DR4-restricted Art v
125-36-specific T cells from DR1-negative, DR4-positive
subjects (n = 8/75) during our intense attempts to estab-
lish TCL and TCC from mugwort-allergic patients. This
discrepancy between HLA-DR4 and -DR1 is striking, as
both molecules belong to the same HLA-DR supertype
that includes DRB1*01:01, DRB5*01:01, DRB1*15:01,
DRB1*04:01, DRB1*07:01, DRB1*09:01, and DRB1*13:02
which all show overlapping peptide-binding repertoires
[11]. It is unlikely that the uniform T cell response to
Art v 1 is due to a restricted TCR Vβ family repertoire,
as we found a broad spectrum of Vβ families in Art v
125-36–specific cells even within single patients [8]. For
DR4-restriction, in general also a broad TCRVβ usage
has been reported [12,13] arguing against a lack of speci-
ficity for Art v 125-36 in the naïve TCR repertoire. Thus,
currently there is no explanation why the DR1-
phenotype is highly prevalent in patients who recognize
Art v 125–36.
In this study, we investigated the molecular back-
ground leading to the preference of HLA-DR1 in the al-
lergic response to the single immunodominant peptide
of Art v 1. Potential differences between HLA-DR1 and
-DR4 molecules regarding peptide binding and require-
ments for TCR recognition were addressed. We com-
pared i) presentation of Art v 125–36 by APC expressing
either HLA-DR1 or -DR4 to allergen-specific T cell lines
(TCL) and clones (TCC) and ii) in vitro binding of Art v
125–36 to HLA-DR 1 and -DR4 molecules using mutated
peptides; furthermore, iii) we performed computer simu-
lations of Art v 125–36-binding to both HLA-molecules
using Molecular Dynamics (MD) simulations.
We found that the majority of Art v 1-specific T cells
recognize synthetic Art v 125–36 and variants thereof as
well as naturally processed peptides presented by DR1
and DR4 in a similar manner. Differences in minimal
epitope recognition suggested structural differences for
binding to the MHC peptide binding groove. MD simu-
lation supported this conclusion demonstrating that the
peptide is much more flexible at both ends and shows a
detached structure at the C-terminus, whereas in DR4
the peptide keeps its extended conformation. Together,
the strong bias of HLA-DR1 in the response to the
immunodominant epitope of Art v 1 apparently is not
primarily due to MHC/peptide binding per se, but rather
seems to be based on structural differences in the TCR-
binding site of the peptide/MHC (pMHC) complex.
Methods
Patients
Eleven mugwort pollen-allergic individuals with typ-
ical clinical history, i.e. recurrent rhinitis/conjunctiv-
itis during late summer, positive skin prick test
(≥3 mm) to mugwort pollen extract (ALK-Abello,
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FEIA ≥ 3) to mugwort pollen (w6; Phadia, Uppsala,
Sweden) were included. All subjects were sensitised
to Art v 1 as determined by IgE-immunoblots as
described [7]. They expressed the following HLA-DR
alleles: Pat.1 DRB1*01, DRB1*11; Pat. 2 DRB1*01,
DRB1*15; Pat. 3 DRB1*01, DRB1*13; Pat. 4 DRB1*01,
DRB1*03 ; Pat. 5 DRB1*01, DRB1*11; Pat. 6 DRB1*01,
DRB1*11; Pat. 7 DRB1*1, DRB1*16; Pat. 8 DRB1*01,
DRB1*13; Pat. 9 DRB1*01, DRB1*16, Pat. 10 DRB1*01,
DRB1*03; Pat. 11 DRB1*01, DRB1*01; The study was
approved by the ethics committee of the Medical Univer-
sity of Vienna (EK No. 497/2005) and informed consent
was obtained from all individuals.
Allergen and peptides
Natural Art v 1 [6] was kindly provided by Matthias Egger
(University of Salzburg, Austria). Synthetic peptides were
obtained from Thermo Electronics (Ulm, Germany). Pur-
ity was >90% as confirmed by HPLC.
Peptide/MHC-binding assay
HLA-DRB1*01:01 and -DRB1*04:01 molecules were puri-
fied from homozygous EBV cells by affinity chromatog-
raphy using mAb L243 as described before [14]. Peptide
binding to HLA-DR molecules was assessed by competi-
tive ELISA. Dilutions were prepared in 10 mM phosphate,
150 mM NaCl, mM n-dodecyl β-D-maltoside, 10 mM
citrate (pH=6.0). The biotinylated reporter peptide
(HA306-318) was incubated with HLA-DRB1*01:01 or
-DRB1*04:01molecules in the presence of serial dilu-
tions of Art v 125-36 or single mutant peptides thereof.
Unlabelled HA306-318 peptide was also introduced to as-
sess the validity of each experiment. After 24 hours of
incubation at 37°C, peptide/MHC-class II complexes
were added to 96 well plates coated with L243 antibody
and incubated at RT for 2 hours. Bound biotinylated
peptides were detected by Streptavidin-alkaline phos-
phatase conjugate (GE healthcare, Saclay, France) and
4-methyl-umbelliferyl phosphate (Sigma-Aldrich, St.
Quentin Fallavier, France) as substrate. Emitted fluores-
cence was measured at 450 nm upon excitation at
365 nm by a Gemini fluorometer (Molecular probes, St
Grégoire, France). Data are expressed as peptide concen-
trations that prevented binding of 50% of the labelled
reference peptide (IC50) HA306-318 (PKYVKQNTLKLAT).
Two independent experiments were performed to evalu-
ate competitive binding. Data were reported as relative af-
finity, i.e. ratio of the IC50 of the peptides to IC50 of the
peptide HA306-318, to account for the differences of sensi-
tivity of the binding assays.
Allergen-specific T cell lines (TCL) and T cell clones (TCC)
Art v 125-36-specific TCL were established from periph-
eral blood mononuclear cells (PBMC) by allergen-specific stimulation with either mugwort pollen extract
or recombinant Art v 1 (Biomay, Vienna, Austria) as
previously described [7]. Art v 125-36-specific TCC were
established from these TCL by limiting dilution [7]. The
two EBV-transformed B cell lines used as APC expressed
comparable amounts of HLA-DR molecules (Figure 1A)
as well as HLA-DQ, -DP- and the co-stimulatory mole-
cules CD80, CD86, CD40 (not shown) on their surface.
TCL or TCC (5 × 104 cells) were stimulated for 3 days
with irradiated (60 Gy) APC and peptides at an
optimum concentration of 3 μM, if not indicated other-
wise. Proliferation was assessed by 3H-thymidine uptake
within the last 16 hours of incubation. Results are shown
in delta cpm (dpm=mean cpm of T cell proliferation
with peptide - mean of T cell proliferation without
peptide).
Flow cytometry
EBV-transformed B cell lines were stained with FITC-
labelled HLA-DR (L243), DP-(B7/21) and DQ-(SK10)
antibodies, CD80 PE, CD86 PE (all BD Biosciences,
Franklin Lakes, NJ) and anti CD40 FITC (BioLegend,
San Diego, CA) and were analyzed on a FACSCanto with
DIVA-software.
HLA-typing
Typing of HLA-DRB1-alleles was performed using a
commercial SSO typing kit (DynalRELI SSO HLA-DRB
Typing kit, Dynal, Bromborrough, UK). Samples with
only a single detectable DRB1-allele were additionally
typed by SSP (Dynal All set SSP DR low resolution,
Dynal). High resolution typing was performed by nu-
cleotide sequencing (BigDye Terminator Cycle Sequen-
cing Kit, ABI, Foster City, CA).
Computer simulation
As starting structure we employed the x-ray structure of
HIV GAG(p24)/HLA-DRB1*01:01, Protein Data Bank
(PDB) [15] accession code [PDB:1sjh] [16], as it com-
prises HLA-DR1 in complex with a 13-mer peptide
(PEVIPMFSALSEG) which also contains isoleucine as
anchor residue similar to Art v 125-36 (KCIEWE-
KAQHGA). We have previously shown that it is suffi-
cient to mutate the side chains of the peptide and leave
its backbone untouched to obtain reliable starting struc-
tures [17]. We selected the side-chain substitution tool
SCWRL [18] to model Art v 125-36 into the MHC bind-
ing groove, since we had found that this tool is the most
accurate regarding peptide/MHC interactions [17,19].
As the x-ray structure of HLA-DRB1*04:01 has not
been resolved yet and HLA-DRB1*01:01 and HLA-
DRB1*04:01 show a sequence identity of 91.58%, we
modelled the structure of DRB1*04:01 directly on the
basis of the previously created HLA-DRB1*01:01
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Figure 1 Presentation of Art v 125-36 by APC expressing HLA-
DR1 or -DR4. A. HLA-DR expression on the EBV cell lines used as APC.
B. Stimulation of TCL (n= 9) and TCC (n=17) derived from 5 different
subjects with an optimum concentration of Art v 125-36 peptide (3 μM).
Box plots indicating the median and quartile ranges are shown.
Background proliferations for DR1 or DR4 plus T cells ranged from
1,002-27,612 cpm and 2406-21054 cpm for TCL and from 1525-
4264 cpm and 370-4270 cpm for TCC). C. T cell reactivity to different
concentrations of Art v 125-36 presented by HLA-DR1 or -DR4 T cells
were stimulated for 3 days with DR1- or DR4-expressing APC and
proliferation was measured by ³H-thymidine uptake during the last
16 hours. Background proliferations were 2796/3056 cpm for Pat 2,
2247/1318 cpm for Pat 8.
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SCWRL yielding 2 (pMHC) complexes with identical
backbone structure and a few side chain mutations in
the MHC.
To perform MD simulations we used the software
package GROMACS 4 [20]. First, we immersed both
complexes into distinct explicit artificial water boxes.
Then we employed a steepest descent energy minimisa-
tion of the complexes to resolve spatial clashes and
simulated warming to 310 K using position restraints.
To provide insight into the dynamics of the pMHC com-
plex at atomic scale, we subsequently carried out MD
simulations [21] to investigate spatial rearrangements of
molecular structures in water for a real time of 30 ns.
All further parameters of the simulation were set
according to Omasits et al. [22].
We evaluated the resulting trajectories using the root







ri tkð Þ  ~rið Þ2
vuut ð1Þ
M is the number of frames, ri tkð Þ is particle with num-
ber i of complex r at time k and ~r is the reference struc-
ture. This method essentially assesses flexibility of
molecules and is implemented in GROMACS in the
g_rmsf function. Furthermore, we calculated the solvent
accessible surface area (SASA) [23] of the side chains of
the peptide by rolling a sphere over them [24]. This
method is implemented in GROMACS in the g_sas
function. Visual pre-screening was performed using
Visual Molecular Dynamics software (VMD, NIH, Uni-
versity of Illinois) [25] and the plug-in vmdICE [26].
Statistics
Significance levels were calculated by using Wilcoxon
signed rank test (SPSS 10.0, Chicago, IL).
Results
Presentation of Art v 125-36 and mutant peptides by HLA-
DR1 and -DR4
To compare the peptide presenting capacity of HLA-
DR1 and DR4, 9 Art v 125-36-specific TCL from 7 differ-
ent patients and 17 Art v 125-36-specific TCC derived
from 5 different patients were stimulated with the syn-
thetic Art v 125-36 12-mer peptide in the presence of
DR1- or DR4-expressing APC. At optimum peptide con-
centrations, TCL proliferated slightly less with DR4, al-
though no statistically significant difference was found
(Figure 1B; median: 31,630 dpm and 25,985 dpm;
p = 0.314). A similar picture was found with the vast ma-
jority of TCC with median proliferations of 36,640 dpm
to DR1 and 24,125 dpm to DR4 (p = 0.193; Figure 1B).
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DR4. At lower concentrations of Art v 125-36, APC
expressing DR1 outperformed those expressing DR4
(Figure 1C).
Next we determined the minimal T cell epitopes
within Art v 125-36 by employing truncated peptides for
stimulation of Art v 125-36-reactive TCL (n = 7; 6 differ-
ent donors) and one TCC (Figure 2A). Minimal epitopes
ranged from 5 to 9 aa for DR1 and from 8 to11 aa for
DR4. Within these minimal epitopes, the central indis-
pensable aa common in all experiments were EWEKA
for DR1 and IEWEKAQH for DR4. In 1 TCC (Pat. 8)
and 3 TCL (Pat. 3, 4, 7), the minimal epitope was shorter
for DR1 than for DR4 (Figure 2A). For 3/7 Art v 125-36-
specific TCL we found identical minimal epitopes for
presentation by either DR-molecule.
In general, for peptides which bind to DR1 or DR4,
the aa in positions p1 (defined as residue which provides
the first anchor), p4, p6 and p9 are supposed to be rele-
vant for HLA-binding, interacting with pockets on the
bottom of the binding groove, so that the surface-
exposed intermittent aa residues at p2/3, p5, p7/8 can
interact with the TCR [11,27]. I27 has previously been
identified as anchor residue p1 of Art v 125-36 [8]. To
identify critical aa residues of Art v 125-36 when pre-
sented either by DR1 or DR4, a set of peptide analoguesLCT
Truncated Peptides Pat. 1 Pat. 2 Pat. 3 Pat. 4 Pat. 4 Pat.5
     Art v 1 25-36 DR1 DR4 DR1 DR4 DR1 DR4 DR1 DR4 DR1 DR4 DR1 D
KCIEWEKAQHGA + + + + + + + + + + +
  CIEWEKAQHGA + + + + + (+) + - + + +
     IEWEKAQHGA (+) - + + + - - - - - +
       EWEKAQHGA - - - - - - - - - - -
          WEKAQHGA - - - - - - - - - - -
              EKAQHGA - - - - - - - - - - -
                 KAQHGA - - - - - - - - - - -
KCIEWE - - - + - - - - - - -
KCIEWEK - - - - - - - - - - -
KCIEWEKA - - - - - - - - - - -
KCIEWEKAQ - - - - - - - - - - -
KCIEWEKAQH + + + + - - + + + + +
KCIEWEKAQHG + + + + + + + - + + +
LCT
 Mutant Peptides Pat. 1 Pat. 2 Pat. 3 Pat. 4 Pat. 7 Pat. 8
Art v 1 25-36 DR1 DR4 DR1 DR4 DR1 DR4 DR1 DR4 DR1 DR4 DR1 D
KCIEWEKAQHGA + + + + + + + + + - +
ACIEWEKAQHGA + + + + + + + + + + +
KAIEWEKAQHGA + - + + + + - + - + +
KCAEWEKAQHGA - - + - - - + - - - -
KCIAWEKAQHGA - - - - + + - - - - -
KCIEAEKAQHGA - - - - - - - - - - -
KCIEWAKAQHGA - - - - + + - - - + -
KCIEWEAAQHGA - - + - - - - - - - -
KCIEWEKGQHGA + + + + + - + + + - +
KCIEWEKAAHGA - + - - - - + + + (+) -
KCIEWEKAQAGA + + + + - - + - - + -
KCIEWEKAQHAA + + + + + + + + - + +
KCIEWEKAQHGG + + + + + - + + - + +
Figure 2 Mapping of minimal T cell epitopes and critical amino acids
was tested with truncated and single mutant Art v 125-36 –peptides. T cells
proliferation was measured by ³H-thymidine uptake during the last 16 hou
by KCIEWEKAQHGA (dpm). Background proliferations for DR1 or DR4 plus T
from 1525-4264 cpm and 370-4270 cpm for TCC.with single aa substitutions was used for T cell stimula-
tions. Besides the crucial anchor residue I27 (p1), W29
(p3) turned out to be indispensable for T cell reactivity
in response to presentation by DR1 and DR4 in all TCL
(from 6 different donors) and TCC (from 2 donors)
tested (Figure 2B). Moreover, E28 (p2), E30 (p4) and
K31 (p5) were critical for more than 70% of the T cell
responses. The residues C26 (p-1), Q33 (p7), H34 (p8)
and A36 (p10) turned out to be additionally important
for 30-50% of T cells, again irrespective of presentation
by DR1 or DR4 (Figure 2B). A32 (p6) and G35 (p9)
represented dispensable residues, possibly due to their
small side chains which limit molecular interactions.
Taken together, for the T cell recognition of Art v 125-36
we found indications for a shorter minimal epitope in DR1,
but no marked differences in the position and number of
residues crucial for interaction with the two HLA-
molecules.
Presentation of naturally-processed Art v 1-peptides by
HLA-DR1 and -DR4 molecules
The experiments performed so far had been based on
synthetic 12-mer peptides which might bind directly to
HLA-DR-molecules expressed on the surface of APC.
To compare intracellular loading of processed Art v 1-
peptides onto DR1- and DR4-molecules, HLA-DR1- orCCT
Pat. 6  R9 Pat. 7
R4 DR1 DR4 DR1 DR4
+ + + + +
+ + + + + K
+ + + + + C
- + - + - I p1
- (+) - - - E p2
- - - - - W p3
- - - - - E p4
- - - - (+) K p5
- - - - - A p6
- + - + - Q p7
- + - + - H p8
+ + + + + G p9
+ + + + + A
CCT
R97 Pat. 7 R114 Pat. 7 R24 Pat. 7 R51 Pat.9
R4 DR1 DR4 DR1 DR4 DR1 DR4 DR1 DR4
+ + + + + + + + -
+ nd nd + + nd nd + + K
+ - - + + - - + + C
- - - - - - - - - I p1
- - - + + - - - - E p2
- - - - - - - - - W p3
- + + - - - - - - E p4
- - - - - + + - - K p5
+ + + + + + - + + A p6
- + + - + + - + + Q p7
- + + - - + + + - H p8
+ + + + + + + - - G p9
+ + - + + nd nd - - A





No. of experiments  
tolerating mutations 
within Art v 125-36 presented by HLA-DR1 or -DR4. T cell reactivity
were stimulated for 3 days with DR1- or DR4-expressing APC and
rs; (+) denotes >50% and (–) >70% reduction of proliferation induced
cells ranged from 1,002-27,612 cpm and 2406-21054 cpm for TCL and
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amounts of Art v 1 and used to stimulate Art v 125-36–
specific T cell cultures. As observed before with synthetic
peptides, the Art v 125-36-specific TCL and 2 TCC prolif-
erated equally well to DR1 or DR4 at optimum concen-
trations. However, at lower concentrations DR1 tended
to be more effective for T cell stimulation (Figure 3).
Binding of Art v 125-36 to HLA-DR1 and -DR4 molecules
The binding capacity of Art v 125-36 to HLA-DRB1*01:01
and –DRB1*04:01 was assessed in competition studies
using HA306-318 as reporter peptide (Table 1). HA306-318,
a high affinity binder to both DR1 and DR4, inhibited it-
self at an IC50 of 1.8 and 11 nM, respectively. Art v 125-36
was found to bind only 15-fold less to both HLA mole-
cules and hence can still be considered a strong binder for
both HLA-molecules. For comparison, we used the neigh-
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Figure 3 Presentation of naturally processed Art v 1-peptides
by DR1- or DR4-expressing APC to Art v 125-36-specific TCL and
TCC. T cells were stimulated for 3 days and proliferation was
measured by ³H-thymidine uptake during the last 16 hours.which showed weak and negligible binding to DR1 or DR4
molecules, respectively.
To allocate the aa residues crucial for anchoring the
peptide within the groove of the HLA molecule, peptides
with single alanine/glycine substitutions at each amino
acid position of Art v 125–36 were used. For both HLA-
molecules a marked loss of binding was obtained by re-
placing I27 (Table 1), clearly confirming that this is the
anchor residue for HLA-DR1 [8] and indicating that the
peptide uses the same anchor residue for binding to
DR4. Weaker binding losses for either molecule were
induced by glycine substitutions of original alanine resi-
dues (A32, A36), which might result from enhancement
of the peptide flexibility due to the special properties of
glycine. Substitution of W29 resulted in a slight effect
on binding to DR1, but not to DR4.
Computer simulation of Art v 125-36 bound to HLA-DR1
and -DR4
In parallel to our in vitro experiments, we investigated
structural differences at the level of MHC/peptide bind-
ing in silico by performing MD simulations. HLA-
DRB1*01:01 and HLA-DRB1*04:01 show an aa sequence
identity of 91.58%. On this basis the overall tertiary
structure is expected to be very similar (see Methods).
However, the binding dynamics of Art v 125-36 to each
HLA-molecule differed markedly during the simulation
time of 30 ns (Figure 4A,B). The interaction with
HLA-DR1 was characterized by highly flexible aa resi-
dues at the N- (K25) and C-terminus (H34, G35 and
A38; Figure 4C) of the peptide with the latter detach-
ing from the binding groove (Figure 4A). In contrast,
only A36 showed high flexibility in the interaction
with HLA-DR4 (Figure 4C). The different dynamics of
Art v 125-36 binding to HLA-DRB1*01:01 and HLA-
DRB1*04:01 were also reflected in the mean solvent
accessible surface area (SASA) (Figure 4D). K31 and
H34 show an increased SASA in HLA-DRB1*01:01
compared to DR4, while the SASA was decreased in
the case of K25, E28, E30 and Q33. Interestingly, the
increased flexibility of Art v 125-36 in association with
HLA-DRB1*01:01 was restricted solely to the peptide
itself while the helices of the alpha- and beta-chains of
DR1 and DR4 showed a similar behaviour in both mole-
cules (Figure 4E,F). For I27 we found a low flexibility and
an almost identical SASA in both complexes indicating
that this residue is stably bound to the MHC in both cases.
Discussion
In spite of the strong association of the allergic immune
response to Art v 1 with HLA-DR1, we have previously
shown that the in vitro binding of its single major T cell
epitope Art v 125-36 to HLA-class II molecules and its
recognition by CD4+ T cells is degenerate [7,8]. In




aratio of IC50 of Art v 1-peptides/HA306-318
HLA-DR1 HLA-DR4
HA304-318 PKYVKQNTLKLAT 1 1
Art v 119-30 NKKCDKKCIEWE >55032 >926
Art v 122-33 CDKKCIEWEKAQ 2016 756
Art v 126-36 KCIEWEKAQHGA 14 15
Ala-25 ACIEWEKAQHGA 9 21
Ala-26 KAIEWEKAGHGA 16 3
Ala-27 KCAEWEKAQHGA 2596 >926 p1
Ala-28 KCIAWEKAQHGA 6 11 p2
Ala-29 KCIEAEKAQHGA 69 14 p3
Ala-30 KCIEWAKAQHGA 6 28 p4
Ala-31 KCIEWEAAQHGA 17 17 p5
Gly-32 KCIEWEKGQHGA 63 149 p6
Ala-33 KCIEWEKAAHGA 11 31 p7
Ala-34 KCIEWEKAQAGA 8 17 p8
Ala-35 KCIEWEKAQHAA 5 5 p9
Gly-36 KCIEWEKAQHGG 74 242
a Relative binding activity. Binding of peptides to HLA-DR1 and -DR4 molecules was assessed by competitive inhibition of the high affinity interaction of
biotinylated-HA306-318 with HLA-DR1 and -DR4 as described in Methods. IC50 values were converted into relative activities (ratio between IC50 value and IC50 of
HA306-318) to take into account the differences of sensitivity of the binding assays. The IC50 of HA306-318 was 1.8 nM for HLA-DR1 and 11 nM for -DR4.
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DR1-restricted TCC, a few TCC from DR1-negative
patients have been isolated that were restricted by DR15,
DR16 or DR3. Although DR4 in general has similar pep-
tide binding characteristics [11] as DR1 and binds Art v
125-36 which can be cross-recognized by DR1-restricted
TCC in vitro [10], no Art v 125-36–specific DR4-restricted
TCC have been isolated so far. Therefore, we expected dif-
ferences in Art v 125-36–peptide binding and T cell activa-
tion between HLA-DR1 and -DR4 and compared anchor
residues and minimal epitopes of the peptide to elucidate
the molecular background for the DR1-biased T cell re-
sponse to Art v 125-36 in more detail. To find further sup-
port for structural differences between Art v 125-36 bound
to HLA-DR1 or HLA-DR4 we also applied MD simula-
tions to the respective pMHC complexes. As there was no
crystal structure available for HLA-DR4, our computer
simulations on peptide/HLA-DR4 interactions were per-
formed on a modeled structure based on the x-ray struc-
ture of HLA-DR1. Nevertheless, this model of HLA-
DRB1*04:01 can be assumed to be reliable, as the se-
quence identity between DR1 and DR4 is above 90% and
models based on a template with a sequence identity
>50% are generally regarded as highly accurate [28]. Fur-
thermore, major changes in the fold of MHC molecules
are extremely unlikely since the MHC superfamily shares
a common overall shape [29].First, we confirmed T cell cross-recognition of Art v
125-36 presented by APC expressing DR4. All T cell cul-
tures used in this study were derived from DR1-positive
donors and had most probably been selected by this
MHC class II restriction element. Still, the vast majority
of TCC (82%) recognized Art v 125-36 presented by DR4
indicating degenerate TCR recognition (Figure 1B).
However, at limiting peptide concentrations DR1-
expressing APC outperformed DR4-expressing APC in
their stimulating capacity (Figure 1C). Natural proces-
sing of antigens generates a pool of peptides with differ-
ent length (mostly 15-18 aa) [30,31] and their
intracellular loading into MHC-class II molecules
underlies editing by HLA-DM [32]. Similar to our syn-
thetic, 12-mer Art v 1-peptides, the peptides resulting
from natural processing were also loaded efficiently into
both DR1- and DR4 molecules as detected by the re-
sponse of Art v 125-36-specific T cells (Figure 3). Here
again, DR1-expressing APC performed better at lower
peptide concentrations than DR4-expressing APC.
Next, differences in the binding behaviour of Art v
125-36 to DR1- and DR4-molecules and T cell stimula-
tory capacity were addressed. In vitro binding assays with
isolated HLA-molecules and single aa mutants of Art v
125-36 confirmed peptide-binding to DR1-molecules with
high affinity and residue I27 as p1-anchor [8]. Moreover,
we found a similar binding affinity and again I27 as
Figure 4 Comparison of the spatial dynamics of HLA-DRB1*01:01 and HLA-DRB1*04:01. (A and B) Cartoon representation of HLA-
DRB1*01:01. Blue: MHC alpha chain; Red: MHC beta chain; Yellow: Equally distributed snapshots of the peptide over the whole simulation time;
Green: Residues differing between HLA-DRB1*01:01 and HLA-DRB1*04:01 which are within 10 Å of the peptide. (C) RMSF of Art v 125-36 bound to
HLA-DRB1*01:01 and HLA-DRB1*04:01. (D) Difference in average SASA between the two complexes. (E) RMSF of the single residues of the helical
segment of the MHC alpha chain. (F) RMSF of the single residues of the helical segment of the MHC beta chain.
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The latter was consistent with our computer simula-
tion data. Notably, the residues at p4, p6, or p9 (E30,
A32, G35) which in general can bind to additionalsecondary binding pockets in the groove of DR1 and
DR4, had no measurable further supporting effects for
Art v 125-36 -binding to either DR molecule, again empha-
sizing the anchor role of I27. A and G by nature do not
Figure 5 Visualisation of Gag p24 34-48 PEVIPMFSALSEGAT
bound to HLA-DRB1*0101 [PDB:1sje] against a sub state of the
Art v 125-36/HLA-DRB1*01:01 simulation. Blue: MHC alpha chain;
Red: MHC beta chain; Yellow: Equally distributed snapshots of Art v
125-36 between nanoseconds 25 and 28; Green: Initial conformation
of Art v 125-36 at the beginning of the simulation. Black: peptide
conformation of the x-ray structures of [PDB:1sjh] Gag p24 34-46
(13mer peptide) and Gag p24 34-48 [PDB:1sje] (15mer peptide).
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not to be relevant for T cell activation (Figure 2B). On the
other hand, E30 (p4) turned out to be important for
most T cell responses (Figure 2). This finding might in-
dicate that, instead of interacting with the HLA-molecule,
E30 may interact with the TCR together with its neigh-
bouring aa W29 (p3). However, the calculated surface
exposition (SASA) of E30 (p4) obtained by computer
modelling was relatively low (Figure 4F) and rather sug-
gested interaction with the MHC molecule. In this case,
the simultaneous presence of the all-dominant I27 in the
A30-mutant peptide apparently prevented in vitro detec-
tion of secondary MHC-binding residues.
Overall, the position and number of Art v 125-36-
residues crucial for T cell reactivity was similar in response
to DR1- or DR4-molecules and focussed on the 5 aa
stretch from I27 to K31. The indispensible residues E28
(p2) W29 (p3), K31 (p5) are located in the core of the
minimal epitopes found. Less frequently Q33 (p7) and
H34 (p8) also formed part of the minimal epitopes
(Figure 2A). Due to their increased flexibility and higher
surface exposition of H34 in DR1 (Figure 4E,F), these aa
may contribute to a more intense TCR-interaction. An in-
fluence of peptide flanking residues (p-1 and p10) on T
cell responses was also observed in a few experiments, but
was not restricted to either DR1- or DR4-presentation.
Although we found similar affinities and structures
(i.e. the same register) for Art v 125-36-binding to DR1 and
DR4 (Table 1), for more than 50% of the Tcells the minimal
epitope was shorter for the DR1-bound peptide
(Figure 2A). In silico, differences in peptide flexibility, indi-
cated by RMSF, became obvious between Art v 125-36
bound to HLA-DR1 or HLA-DR4 with advanced simula-
tion time. In DR1 the peptide was more flexible at both
ends and detached from the MHC-molecule at the C-
terminus (Figure 4A-C). In essence, the parts of the Art v
1-peptide with lower ranges in RMSF, i. e. less flexibility, re-
flect the common core of the minimal peptide regions as
defined by our in vitro experiments for DR1 (IEWEK) or
DR4 (CIEWEKAQH). Thus these peptide ranges might de-
fine the parts of Art v 125-36 buried in the MHC-binding
groove. Further indications for structural differences be-
tween the Art v 125-36 /DR1 or -DR4 complex were the
overall discrepancies obtained for surface exposition
(SASA, Figure 4D). As compared to DR4, the C-terminal
aa residues in DR1 were more solvent-exposed, while the
N-terminal residues were less exposed. In addition, K31 at
position p5, classically the central solvent TCR-exposed
residue in MHC class II [33], showed a markedly higher
SASA value in complex with DR1 than with DR4. These
differences may indicate better access of the TCR to the
core and C-terminus of the Art v 1-peptide in DR1.
Our simulations were based on the crystal structure of
the 13-mer peptide HIV Gag p24 34-46 PEVIPMFSALSEGbound to HLA-DRB1*0101 [PDB:1sjh]. Interestingly, a
congruent crystal structure exists [PDB:1sje] represent-
ing HLA-DRB1*01:01 with the 15-mer peptide HIV
Gag p24 34-48 containing 2 additional C-terminal aa resi-
dues (A, T). While the 13 N-terminal residues of the pep-
tide show an essentially identical spatial arrangement as the
Art v 1-complex at the initial configuration [16,26], these
two residues reach out of the MHC binding groove and
build a hairpin turn which has been reported to be essential
for T cell recognition of this HIV Gag p24–epitope [16,34].
Intriguingly, this hairpin structure resembles certain sub-
states of the detached C-terminal end of the Art v 125-36 /
HLA-DRB1*01:01 complex as shown in Figure 5. Within
61 published crystal structures of pMHC class II molecules
that contain at least short peptide flanking regions, we
found in about 10% of them structures divergent from the
canonical stretched conformation such as detachments,
loop-like structures or hairpin turns. These structures most
likely are important for T cell reactivity. We have previously
reported effects of such protruding peptide segments on T
cell activation for peptide flanking regions [34] and altered
peptide ligands with high sequence similarity [35]. Thus,
we suggest that the C-terminal Art v 125-36-residues pro-
truding from the peptide binding groove are relevant for
interactions with TCR in vivo.
An alternative interpretation for the lack of DR4-
responses to Art v 1 in the population may be a poten-
tial negative influence of flanking regions in naturally
processed peptides selectively on HLA-DR4. However,
the fact that DR1-restricted T cells also respond well to
naturally processed, DR4-presented Art v 1 (Figure 3) at
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would only be of minor relevance.
In summary, compared to DR4, DR1 allowed T cell ac-
tivation of shorter minimal epitopes within Art v 125-36
and at lower peptide concentrations. However, the differ-
ences obtained in our experimental assays may not
clearly explain the high association of Art v 125-36-
recognition and HLA-DRB1*01. We used allergen-
specific effector T cells with a very high sensitivity for
antigen-specific activation in our study. However, the
threshold level for activation of naïve T cells is much
higher. Therefore, we suggest that at much lower aller-
gen-concentrations, i.e. at conditions present in the
human body, the observed differences become much
more relevant in vivo, so that DR1- but not DR4-
expressing APC are capable of activating cognate T cells.
This assumption would be backed by the fact that we
could not establish DR4-restricted TCC from any of our
DR4-expressing mugwort-allergic patients.
Conclusions
We used the T cell response to the immunodominant
epitope of Art v 1 as a model to study p/MHC/TCR
interactions in order to explain why a peptide with
degenerate MHC-class II binding behaviour causes
primarily HLA-DR1-restricted immune responses. The
combination of experimental and in silico data suggested
that TCR recognition of this peptide in the context of
DR1 may be promoted by distinctive structural features
in the pMHC complex leading e.g. to superior TCR ac-
cessibility and preferential priming in vivo.
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